Recently, there has been confusion for international travelers looking to protect themselves from dengue disease, which is transmitted to people by mosquitoes.
In January 2024, Sanofi-Pasteur announced that they would stop manufacturing the U.S. FDA-approved Dengvaxia® vaccine for children due to a lack of demand in the global market.
Second-Gen Dengue Vaccine Found in 24 Countries
$150 Million Accelerates Scientific Concepts Starting in Respiratory and Immunology Medicines and Vaccines
GSK plc and Flagship Pioneering today announced they have entered a collaboration to discover and develop a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance combines GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, including its novel modalities and technologies, to make significant advances in healthcare.
$150 Million Accelerates Scientific Concepts Starting in Respiratory and Immunology Medicines and Vaccines
GSK plc and Flagship Pioneering today announced they have entered a collaboration to discover and develop a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance combines GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, including its novel modalities and technologies, to make significant advances in healthcare.